AU2016372048B2 - Heteroarylhydroxypyrimidinones as agonists of the APJ receptor - Google Patents

Heteroarylhydroxypyrimidinones as agonists of the APJ receptor Download PDF

Info

Publication number
AU2016372048B2
AU2016372048B2 AU2016372048A AU2016372048A AU2016372048B2 AU 2016372048 B2 AU2016372048 B2 AU 2016372048B2 AU 2016372048 A AU2016372048 A AU 2016372048A AU 2016372048 A AU2016372048 A AU 2016372048A AU 2016372048 B2 AU2016372048 B2 AU 2016372048B2
Authority
AU
Australia
Prior art keywords
substituted
independently selected
alkyl
heterocyclyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016372048A
Other languages
English (en)
Other versions
AU2016372048A1 (en
Inventor
Donna M. Bilder
Robert Paul Brigance
Heather Finlay
R. Michael Lawrence
Wei Meng
Michael C. Myers
Zulan Pi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2016372048A1 publication Critical patent/AU2016372048A1/en
Application granted granted Critical
Publication of AU2016372048B2 publication Critical patent/AU2016372048B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
AU2016372048A 2015-12-16 2016-12-15 Heteroarylhydroxypyrimidinones as agonists of the APJ receptor Ceased AU2016372048B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267997P 2015-12-16 2015-12-16
US62/267,997 2015-12-16
PCT/US2016/066750 WO2017106396A1 (en) 2015-12-16 2016-12-15 Heteroarylhydroxypyrimidinones as agonists of the apj receptor

Publications (2)

Publication Number Publication Date
AU2016372048A1 AU2016372048A1 (en) 2018-08-02
AU2016372048B2 true AU2016372048B2 (en) 2021-02-04

Family

ID=57708840

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016372048A Ceased AU2016372048B2 (en) 2015-12-16 2016-12-15 Heteroarylhydroxypyrimidinones as agonists of the APJ receptor

Country Status (21)

Country Link
US (1) US10669261B2 (enExample)
EP (1) EP3390400B1 (enExample)
JP (1) JP6948322B2 (enExample)
KR (1) KR102742744B1 (enExample)
CN (1) CN108602813B (enExample)
AR (1) AR107061A1 (enExample)
AU (1) AU2016372048B2 (enExample)
BR (1) BR112018012112A2 (enExample)
CA (1) CA3008630A1 (enExample)
CL (1) CL2018001621A1 (enExample)
CO (1) CO2018007221A2 (enExample)
EA (1) EA036736B1 (enExample)
ES (1) ES2854733T3 (enExample)
HK (1) HK1255163A1 (enExample)
IL (1) IL259947B (enExample)
MX (1) MX380669B (enExample)
PE (1) PE20181487A1 (enExample)
SG (1) SG11201804674UA (enExample)
TW (1) TW201725203A (enExample)
UY (1) UY37026A (enExample)
WO (1) WO2017106396A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3303330T3 (pl) 2015-06-03 2019-10-31 Bristol Myers Squibb Co Agoniści 4 - hydroksy - 3 - ( heteroarylo ) pirydyno - 2 - onowi receptora apj do stosowania w leczeniu zaburzeń sercowo-naczyniowych
UY36949A (es) 2015-10-14 2017-04-28 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware 2,4-dihidroxi-nicotinamidas como agonistas de apj
EA037257B1 (ru) 2015-12-04 2021-02-26 Бристол-Маерс Сквибб Компани Новые агонисты рецептора апелина и способы применения
MA55064A (fr) 2015-12-16 2021-09-29 Loxo Oncology Inc Composés utilisés comme inhibiteurs de kinase
CN109195963B (zh) 2016-03-24 2021-04-23 百时美施贵宝公司 作为apj激动剂的6-羟基-4-氧代-1，4-二氢嘧啶-5-甲酰胺
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US10889565B2 (en) 2016-06-14 2021-01-12 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists
CN109311821B (zh) 2016-06-14 2022-10-14 百时美施贵宝公司 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮
CN110072850B (zh) 2016-10-14 2023-07-21 百时美施贵宝公司 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060805A1 (en) * 2000-02-16 2001-08-23 Smithkline Beecham P.L.C. Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
WO2015184011A2 (en) * 2014-05-28 2015-12-03 Sanford-Burnham Medical Research Institute Agonists of the apelin receptor and methods of use thereof
WO2016196771A1 (en) * 2015-06-03 2016-12-08 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
US6174998B1 (en) 1996-03-12 2001-01-16 Roche Diagnostics Gmbh C-nucleoside derivatives and their use in the detection of nucleic acids
JPH08311041A (ja) 1995-03-16 1996-11-26 Takeda Chem Ind Ltd 複素環化合物およびその剤
KR100579765B1 (ko) 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
CA2416248A1 (en) 2000-07-18 2002-01-24 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
WO2002081454A1 (en) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO2003094839A2 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
WO2003099211A2 (en) 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
EP1620428A1 (en) 2003-04-23 2006-02-01 Pharmacia & Upjohn Company LLC Substituted pyrimidinones and pyrimidinthiones as crf antagonists
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20050197327A1 (en) 2003-11-03 2005-09-08 Gustave Bergnes Compounds, compositions, and methods
US7625912B2 (en) 2003-12-19 2009-12-01 Merck & Co. Inc Mitotic kinesin inhibitors
JP4517349B2 (ja) 2004-07-28 2010-08-04 宇部興産株式会社 ピリミジン−４−オン化合物の製造方法
DE102005025315A1 (de) 2005-06-02 2006-12-14 Merck Patent Gmbh Ionische Flüssigkeiten mit niedriger Viskosität
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
EP1963329B1 (en) 2005-11-30 2013-01-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
US8367845B2 (en) 2006-04-21 2013-02-05 The Trustees Of Boston University Ionic viscoelastics and viscoelastic salts
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
ES2527722T3 (es) 2006-10-10 2015-01-28 Proionic Gmbh & Co Kg Método para reaccionar 2-carboxilatos 1,3-heteroaromáticos con agua
JP2010519204A (ja) 2007-02-16 2010-06-03 アムジエン・インコーポレーテツド 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用
WO2009152902A2 (en) 2008-05-28 2009-12-23 Merck Patent Gmbh, Ionic liquids
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
WO2010072696A2 (de) 2008-12-22 2010-07-01 Basf Se Mischungen hydrophober und hydrophiler ionischer flüssigkeiten und ihre verwendung in flüssigkeitsringverdichtern
TW201100411A (en) 2009-05-21 2011-01-01 Chlorion Pharma Inc Pyrimidines as novel therapeutic agents
US9212130B2 (en) 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
CN103597646A (zh) 2011-05-31 2014-02-19 默克专利股份有限公司 电解质组合物
TWI567084B (zh) 2011-05-31 2017-01-21 麥克專利有限公司 含有氫－三氰－硼酸根陰離子之化合物
CN102903954B (zh) 2011-07-25 2015-06-03 微宏动力系统（湖州）有限公司 含有离子液体电解质的锂离子二次电池
DE102012006896A1 (de) 2012-04-05 2013-10-10 Merck Patent Gmbh Silikate mit organischen Kationen
EP3409666A3 (en) 2012-06-07 2019-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
CA2885272A1 (en) * 2012-09-21 2014-03-27 Sanofi Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators
WO2014056844A1 (en) 2012-10-10 2014-04-17 Basf Se Ionic liquids based on oxalic acid mono esters
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
US20150291596A1 (en) 2012-11-16 2015-10-15 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
WO2014207100A1 (en) 2013-06-27 2014-12-31 Basf Se A process for coating paper with cellulose using a solution containing cellulose
DE102013016324A1 (de) 2013-10-04 2015-04-09 Merck Patent Gmbh Perfluoralkylfluor- oder Perfluoralkylchlorgermanate
CA2930343C (en) 2013-11-29 2021-06-08 Proionic Gmbh Method for curing an adhesive using microwave irradiation
KR101550846B1 (ko) 2014-01-29 2015-09-07 한국과학기술연구원 단일공정을 이용한 탄소소재의 다원소 도핑방법 및 그 용도
KR101531023B1 (ko) 2014-05-27 2015-06-23 한국과학기술연구원 열분해 가스 도핑에 의한 고강도 고전도성 탄소나노튜브섬유의 제조방법 및 이에 따라 제조된 탄소나노튜브섬유
MX387055B (es) * 2014-06-06 2025-03-19 Res Triangle Inst Agonistas del receptor de apelina (apj) y usos de los mismos.
WO2016074757A1 (de) 2014-11-11 2016-05-19 Merck Patent Gmbh Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren
UY36949A (es) 2015-10-14 2017-04-28 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware 2,4-dihidroxi-nicotinamidas como agonistas de apj
EA037257B1 (ru) 2015-12-04 2021-02-26 Бристол-Маерс Сквибб Компани Новые агонисты рецептора апелина и способы применения
CN109195963B (zh) 2016-03-24 2021-04-23 百时美施贵宝公司 作为apj激动剂的6-羟基-4-氧代-1，4-二氢嘧啶-5-甲酰胺
US10889565B2 (en) 2016-06-14 2021-01-12 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists
CN109311821B (zh) 2016-06-14 2022-10-14 百时美施贵宝公司 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮
CN110072850B (zh) 2016-10-14 2023-07-21 百时美施贵宝公司 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060805A1 (en) * 2000-02-16 2001-08-23 Smithkline Beecham P.L.C. Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
WO2015184011A2 (en) * 2014-05-28 2015-12-03 Sanford-Burnham Medical Research Institute Agonists of the apelin receptor and methods of use thereof
WO2016196771A1 (en) * 2015-06-03 2016-12-08 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders

Also Published As

Publication number Publication date
PE20181487A1 (es) 2018-09-18
US20180362508A1 (en) 2018-12-20
CL2018001621A1 (es) 2018-08-03
CA3008630A1 (en) 2017-06-22
IL259947A (en) 2018-07-31
IL259947B (en) 2020-10-29
AR107061A1 (es) 2018-03-14
EA201891336A1 (ru) 2019-01-31
WO2017106396A1 (en) 2017-06-22
JP2018538304A (ja) 2018-12-27
CO2018007221A2 (es) 2018-07-19
JP6948322B2 (ja) 2021-10-13
UY37026A (es) 2017-06-30
ES2854733T3 (es) 2021-09-22
US10669261B2 (en) 2020-06-02
EA036736B1 (ru) 2020-12-14
EP3390400B1 (en) 2021-01-20
AU2016372048A1 (en) 2018-08-02
MX380669B (es) 2025-03-12
CN108602813B (zh) 2021-10-29
KR20180095577A (ko) 2018-08-27
HK1255163A1 (zh) 2019-08-09
SG11201804674UA (en) 2018-06-28
BR112018012112A2 (pt) 2018-12-04
CN108602813A (zh) 2018-09-28
KR102742744B1 (ko) 2024-12-12
EP3390400A1 (en) 2018-10-24
TW201725203A (zh) 2017-07-16
MX2018007155A (es) 2018-08-15

Similar Documents

Publication Publication Date Title
AU2016372048B2 (en) Heteroarylhydroxypyrimidinones as agonists of the APJ receptor
US12168655B2 (en) Apelin receptor agonists and methods of use
US10336739B2 (en) 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists
US10669258B2 (en) 3-sulfonyl-5-aminopyridine-2,4-diol APJ agonists
US10392347B2 (en) 2,4-dihydroxy-nicotinamides as APJ agonists
US10889565B2 (en) 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists
AU2017238504B2 (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
KR102384668B1 (ko) Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired